Cite
APA Citation
Arkenau, H., Italiano, A., Mak, G., Toulmonde, M., Baird, R., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., & Spicer, J. (2018). an extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European journal of cancer, 103, 17–23. http://access.bl.uk/ark:/81055/vdc_100070088909.0x000028